Nick Waddell

With some new blue chip investors on board, investors should be taking a long look at Volatus Aerospace, says analyst Rob Goff

Cord-cutting is on the rise and it’s just one reason Canada’s Sabio Holdings is growing rapidly.

Dr. Essam Hamza says all the pieces are in place for Treatment.com AI to have success.

On October 9, FTG closed at an all-time high after posting third quarter results that showed EBITDA and revenue were way up.

The stock has been on fire since August and CEO Corey Giasson says innovation is much of the reason for the success of Mustgrow Biologics.

Following third quarter results that came in lower than his expectations, analyst Kirk Wilson has maintained his “Buy” rating on Polaris Renewable Energy

A Canadian healthcare technology company is poised to benefit from the next four years of American leadership, says one analyst

Following the company’s second quarter results, RBC Dominion Securities analyst James McGarragle has raised his price target on CAE.

With its second quarter results in the books, Raymond James analyst Michael W. Freeman has raised its price target on Medexus Pharmaceuticals.

In the wake of the latest GDP numbers, another 50 basis point cut is on the way. That’s the opinion of Nathan Janzen at the Royal Bank of Canada.